Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.

Zhou D. et al, (2024), Nature communications, 15

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.

Michael BD. et al, (2023), Nature communications, 14

Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera

Roper KJ. et al, (2023), Scientific Reports, 13

Structural comparison of typical and atypical E2 pestivirus glycoproteins.

Aitkenhead H. et al, (2023), Structure (London, England : 1993)

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.

Bou-Antoun S. et al, (2023), The Journal of antimicrobial chemotherapy, 78, ii37 - ii42

Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.

Bešević J. et al, (2023), Journal of epidemiology and community health

Experimental phasing opportunities for macromolecular crystallography at very long wavelengths.

El Omari K. et al, (2023), Commun Chem, 6

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.

Ni T. et al, (2023), iScience, 26

Accelerating drug target inhibitor discovery with a deep generative foundation model.

Chenthamarakshan V. et al, (2023), Science advances, 9

Broadly neutralizing antibodies against COVID-19.

Zhou D. et al, (2023), Current opinion in virology, 61

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Ragonnet-Cronin M. et al, (2023), Nature communications, 14

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface

Zhang P. et al, (2023)

Cryogenic electron ptychographic single particle analysis with wide bandwidth information transfer.

Pei X. et al, (2023), Nature communications, 14

Investigation of the milling characteristics of different focused-ion-beam sources assessed by three-dimensional electron diffraction from crystal lamellae.

Parkhurst JM. et al, (2023), IUCrJ

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.

Wei J. et al, (2023), Nature communications, 14

Characterization of the rotavirus assembly pathway in situ using cryoelectron tomography.

Shah PNM. et al, (2023), Cell Host Microbe, 31, 604 - 615.e4

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271

Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2

Stuart D. et al, (2023)

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.

Siggins MK. et al, (2023), Immunology, 168, 473 - 492

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.

Goldswain H. et al, (2023), Genome biology, 24

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?